Overview

These transgenic mice express the human MCL1 under the direction of the human endogenous promoter. Mice exhibit enlarged spleens, increased total splenocyte number, lymph node enlargement and a high probability of developing lymphomas. This transgenic mouse strain may be useful in studies related to tumorigenesis and inhibition of tumorigenesis in the presence of a viability-promoting BCL2 family member.

Donating Investigator

Ruth W. Craig, Dartmouth Medical School

Genetic overview

Genetic Background	Generation

Tg(MCL1)8Caig

Allele Type
Transgenic (Inserted expressed sequence, Humanized sequence)

View Genetics

Research Applications

Cancer Research

View All Research Applications

Base Price

Starting at:

$2,854.50 Domestic price Cryo Recovery

View Price List

Details

Detailed Description

These transgenic mice express the human MCL1 under the direction of the human MCL1 promoter. Expression of the human MCL1 protein was immunodetectable. Mice hemizygous for the transgene exhibited human MCL1 in bone marrow, lymph node, thymus and spleen (both B- and T-cell populations). Low levels of transgene expression was found in kidney, small intestine, uterus, lung and liver. The majority of the transgenic mice had enlarged spleens, with an increased total splenocyte number (both B- and T-cell). Transgenic mice displayed an increase of myeloid cells relative to lymphoid cells in bone marrow, and an enhanced viability of hematopoietic and lymphoid cells (B, T and myeloid) at immature and mature stages of development. In transgenic mice from 6 to 11 months of age, 27% displayed lymph node enlargement. Transgenic mice had an 88% probability of developing pathologic lymph node disease, and a 60% probability of developing disseminated disease from 6 months to 2 years of age. The lymphomas in the transgenic mice were predominantly of clonal B-cell origin and displayed a variety of histological subtypes including follicular lymphoma and diffuse large-cell lymphoma. This transgenic mouse strain represents a model that may be useful in studies related to tumorigenesis and inhibition of tumorigenesis in the presence of a viability-promoting BCL2 family member.

Development

A transgenic construct containing the entire human MCL1 gene, including the endogenous MCL1 promoter, was microinjected into B6;SJLF1 fertilized oocytes. Founder animals were bred to C57BL/6J mice.

Expression Data

Expressed Gene	MCL1, MCL1, BCL2 family apoptosis regulator, human
Site of Expression

Selected References

Zhou P; Qian L; Bieszczad CK; Noelle R; Binder M; Levy NB; Craig RW. 1998. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92(9):3226-39PubMed: 9787159 MGI: J:50604

View All References

Genetics

Tg(MCL1)8Caig

Allele Symbol: Tg(MCL1)8Caig

Allele Name	transgene insertion 8, Ruth W Craig
Allele Type	Transgenic (Inserted expressed sequence, Humanized sequence)
Allele Synonym(s)
Gene Symbol and Name	Tg(MCL1)8Caig, transgene insertion 8, Ruth W Craig
Gene Synonym(s)
Promoter	MCL1, MCL1, BCL2 family apoptosis regulator, human
Expressed Gene	MCL1, MCL1, BCL2 family apoptosis regulator, human
Strain of Origin	(C57BL/6 x SJL)F1
Chromosome	UN
Molecular Note	The transgene contains the entire human MCL1 gene, including the endogenous MCL1 promoter. Hemizygous transgenic mice expressed human MCL1 in bone marrow, lymph node, thymus, and spleen (both B- and T-cell populations). Low levels of transgene expression were found in the kidney, small intestine, uterus, lung and liver.
Mutations Made By	Ruth Craig, Dartmouth Medical School

Disease/Phenotype

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Cancer Research
- Increased Tumor Incidence
  - Lymphomas

Mammalian Phenotype Terms by Genotype

The following phenotype relates to a compound genotype created using this strain

Genotype: Tg(MCL1)8Caig/0
involves: C57BL/6 * SJL

cellular phenotype

abnormal macrophage apoptosis
- bone marrow derived macrophages have significantly less apoptosis than controls 20 hours after infection with pneumococcal infection
- by 48 hours after infection, apoptosis levels are similar to that in wild-type controls suggesting pneumococcal-associated apoptosis is delayed rather than suppressed

abnormal mast cell differentiation
- immortalized immature mast cells can be cultured out of spleens with a frequency of 3 x 10^-5, which is at least 1000-fold more frequent than controls

abnormal monocyte differentiation
- immortalized monocytes can be cultured of out of spleens unlike with wild-type controls

decreased B cell apoptosis
- B cells present in splenocyte culture die-off at about half the rate as wild-type B cells do

decreased splenocyte apoptosis
- 25% of splenocytes survive four days of culture while all of controls die
- cultured splenocytes die off at a rate about half that of controls

decreased T cell apoptosis
- T cells are still present after 3 days of splenocyte culture compared to no T cells surviving culture of wild-type splenocytes

growth/size/body region phenotype

spleen hyperplasia
- spleens have 1.6-fold higher number of cells and are visibly larger

hematopoietic system phenotype

abnormal common myeloid progenitor cell morphology
- there is a doubling in the number of myeloid progenitors found in the bone marrow
- these progenitors exhibit enhanced survival in the absence of growth factors

abnormal immature B cell morphology
- however, there is a 5-fold increase in the number of B cell precursors found in bone marrow culture compared to controls
- ratio of myeloid to B cell precursors is 2.2:1 versus 1.3:1 in wild-type bone marrow

abnormal leukocyte physiology
- including IL-3 in the culture greatly enhanced survival of transgenic myeloid cells but not non-transgenic myeloid cells
- myeloid cells present in splenocyte culture die-off at a slower rate than controls

abnormal macrophage apoptosis
- bone marrow derived macrophages have significantly less apoptosis than controls 20 hours after infection with pneumococcal infection
- by 48 hours after infection, apoptosis levels are similar to that in wild-type controls suggesting pneumococcal-associated apoptosis is delayed rather than suppressed

abnormal mast cell differentiation
- immortalized immature mast cells can be cultured out of spleens with a frequency of 3 x 10^-5, which is at least 1000-fold more frequent than controls

abnormal monocyte differentiation
- immortalized monocytes can be cultured of out of spleens unlike with wild-type controls

decreased B cell apoptosis
- B cells present in splenocyte culture die-off at about half the rate as wild-type B cells do

decreased splenocyte apoptosis
- 25% of splenocytes survive four days of culture while all of controls die
- cultured splenocytes die off at a rate about half that of controls

decreased T cell apoptosis
- T cells are still present after 3 days of splenocyte culture compared to no T cells surviving culture of wild-type splenocytes

extramedullary hematopoiesis
- extramedullary hematopoiesis is very active in these mice

increased erythroid progenitor cell number
- there is a doubling in the number of erythroid progenitors found in the bone marrow
- these progenitors exhibit enhanced survival in the absence of growth factors

increased spleen white pulp amount
- mice rarely have expansion of the white pulp

increased thymocyte number
- 2 of 9 mice have increased numbers of thymocytes

spleen hyperplasia
- spleens have 1.6-fold higher number of cells and are visibly larger

immune system phenotype

abnormal immature B cell morphology
- however, there is a 5-fold increase in the number of B cell precursors found in bone marrow culture compared to controls
- ratio of myeloid to B cell precursors is 2.2:1 versus 1.3:1 in wild-type bone marrow

abnormal leukocyte physiology
- including IL-3 in the culture greatly enhanced survival of transgenic myeloid cells but not non-transgenic myeloid cells
- myeloid cells present in splenocyte culture die-off at a slower rate than controls

abnormal macrophage apoptosis
- bone marrow derived macrophages have significantly less apoptosis than controls 20 hours after infection with pneumococcal infection
- by 48 hours after infection, apoptosis levels are similar to that in wild-type controls suggesting pneumococcal-associated apoptosis is delayed rather than suppressed

abnormal mast cell differentiation
- immortalized immature mast cells can be cultured out of spleens with a frequency of 3 x 10^-5, which is at least 1000-fold more frequent than controls

abnormal monocyte differentiation
- immortalized monocytes can be cultured of out of spleens unlike with wild-type controls

decreased B cell apoptosis
- B cells present in splenocyte culture die-off at about half the rate as wild-type B cells do

decreased splenocyte apoptosis
- 25% of splenocytes survive four days of culture while all of controls die
- cultured splenocytes die off at a rate about half that of controls

decreased T cell apoptosis
- T cells are still present after 3 days of splenocyte culture compared to no T cells surviving culture of wild-type splenocytes

increased spleen white pulp amount
- mice rarely have expansion of the white pulp

increased susceptibility to bacterial infection
- all transgenic mice with more than 10² CFU in the lung develope bacteremia, which does not occur in nontransgenic mice
- at higher infection doses, the amount of CFUs in the lung is a log unit higher than that in wild-type mice
- mice fail to clear bacteria after infection with 10⁴ CFU compared to controls
- pneumococcal-associated macrophage apoptosis is lower by about half in these mice 14 hours after infection

increased thymocyte number
- 2 of 9 mice have increased numbers of thymocytes

spleen hyperplasia
- spleens have 1.6-fold higher number of cells and are visibly larger

neoplasm

increased follicular lymphoma incidence
- B cells lacking IgM expression constitute the majority of the large cells in the cases of disseminated disease
- Ig-heavy chain analysis of lymphomas reveals clonal rearrangement of the immunoglobulin heavy-chain locus (except in the one case of T cell lymphoma) demonstrating a B cell origin
- some cases present a polymorphic cytology consisting of a heterogeneous mixture of small and large lymphocytes
- the majority of lymphomas are diffuse large-cell lymphoma with B-cell origins or indeterminate origin

increased lymphoma incidence
- about 27% of mice at 6-11 months of age develop lymphomas of various subtypes
- in the remaining one third of affected transgenic animals, disease was localized to mesenteric lymph nodes or presented as extra-nodal lymphoma in the gastrointestinal tract
- lymphomas develop in about 50% of transgenic mice at 18 to 23 months of age and in about 65% of mice at 2 years of age compared to 12% of non-transgenic mice by 2 years of age
- two-thirds of the cases involve disseminated disease affecting lymph nodes (mesenteric, renal, mediastinal, and cervical areas) and other tissues (liver, lung, kidney)

increased T cell derived lymphoma incidence
- non-disseminated T cell lymphoma occurred in 1 case out of 18 total lymphoma cases

endocrine/exocrine gland phenotype

increased T cell derived lymphoma incidence
- non-disseminated T cell lymphoma occurred in 1 case out of 18 total lymphoma cases

increased thymocyte number
- 2 of 9 mice have increased numbers of thymocytes

References

Zhou P; Qian L; Bieszczad CK; Noelle R; Binder M; Levy NB; Craig RW. 1998. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92(9):3226-39PubMed: 9787159 MGI: J:50604

Additional References

Zhou P; Levy NB; Xie H; Qian L; Lee CY; Gascoyne RD; Craig RW. 2001. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 97(12):3902-9PubMed: 11389033 MGI: J:69755

Additional - Tg(MCL1)8Caig related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Standard PCR:Tg(MCL1)8Caig-alternate1
- Genotyping resources and troubleshooting
Breeding Considerations

This transgenic strain was created on a B6;SJLF1 background. Founder animals were bred to normal C57BL/6J mice to produce hemizygotes. These mice are maintained by mating hemizygotes. Female homozygotes are fertile and do not mate.
- Additional Breeding and Husbandry Support
Citation
When using the B6;SJL-Tg(MCL1)8Caig/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #004187 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Pricing & Availability

Cryo Recovery

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service/Product	Description	Price
	Hemizygous or Non carrier for Tg(MCL1)8Caig

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Notice to customers in Canada.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Expression Data

Selected References

Tg(MCL1)8Caig

Allele Symbol: Tg(MCL1)8Caig

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Tg(MCL1)8Caig/0involves: C57BL/6 * SJL

cellular phenotype

growth/size/body region phenotype

hematopoietic system phenotype

immune system phenotype

neoplasm

endocrine/exocrine gland phenotype

References

Additional References

Additional - Tg(MCL1)8Caig related

Genotyping Protocols

Breeding Considerations

Citation

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Live Mouse

Cryorecovery - Pricing

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms Of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Genotype: Tg(MCL1)8Caig/0
involves: C57BL/6 * SJL